Beijing Tongren Hospital

Running trials

• Recruiting

  Prospective ctDNA Testing in Large B-Cell Lymphoma

  NCT07878351· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· Source

• Recruiting

  Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

  NCT07523737· Phase 2· Source

• Recruiting

  A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

  NCT07409428· Phase 3· Source

• Not yet recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT07465120· Phase 2· Source

• Recruiting

  A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

  NCT07777861· Phase 2· Source

• Recruiting

  Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)

  NCT07352891· Source

• Not yet recruiting

  To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

  NCT07406438· Phase 1· Source

• Not yet recruiting

  Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)

  NCT07332494· Source

• Recruiting

  A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

  NCT07417566· Phase 1· Source

• Recruiting

  A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

  NCT07189065· Phase 2· Source

• Recruiting

  Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

  NCT07371923· Phase 2· Source

• Recruiting

  Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

  NCT07439133· Phase 3· Source

• Recruiting

  Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

  NCT07040072· Phase 1· Source

• Not yet recruiting

  Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial

  NCT07133932· Source

• Recruiting

  Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

  NCT07348302· Phase 3· Source

• Recruiting

  Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities

  NCT07888114· Phase 1· Source

• Recruiting

  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

  NCT06760039· Phase 1/2· Source

• Recruiting

  Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

  NCT07097805· Source

• Recruiting

  Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

  NCT06510283· Phase 2· Source

• Active, not recruiting

  A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

  NCT06666855· Phase 3· Source

• Recruiting

  ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06775860· Phase 3· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Recruiting

  A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

  NCT06413654· Phase 2/3· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

  NCT05562947· Phase 3· Source

• Recruiting

  GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery

  NCT06468852· Source

• Active, not recruiting

  Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

  NCT06093841· Phase 2· Source

• Recruiting

  An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

  NCT05908695· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

  NCT05954910· Source

• Recruiting

  Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

  NCT06102395· Phase 3· Source

• Recruiting

  Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

  NCT05672121· Phase 1/2· Source

• Active, not recruiting

  A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

  NCT07226752· Phase 3· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Active, not recruiting

  Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

  NCT06196827· Phase 1· Source

• Recruiting

  Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography

  NCT05644548· Source

• Recruiting

  Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

  NCT04930432· Phase 1/2· Source

• Active, not recruiting

  Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

  NCT04152499· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Diffuse large B-cell lymphoma6 recruiting
• Head and neck cancer4 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Coronary artery disease2 recruiting
• Macular degeneration2 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Diabetic eye disease1 recruiting
• Glaucoma1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

  NCT07060885· Phase 3· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Source

• Completed

  Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

  NCT06648772· Phase 3· Source

• Completed

  Minimally Invasive Surgery and rhTNK-tPA for Intracerebral Hemorrhage Evacuation

  NCT06668441· Phase 1· Source

• Completed

  Treatment of Moderate to Severe Plaque Psoriasis

  NCT06542614· Phase 2· Source

• Completed

  Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

  NCT06436768· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Source

• Completed

  CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

  NCT07461831· Phase 2· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Source

• Completed

  Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

  NCT04849351· Phase 2· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Source

• Completed

  Development and Validation of a Machine Learning Model for Differentiating Diabetic Kidney Disease and Non-Diabetic Kidney Disease in Type 2 Diabetes

  NCT07672639· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Source

Trial sites

• Beijing Tongren Hospital18 trials
• Beijing Tongren Hospital, Capital Medical University35 trials
• Beijing Tongren Hospital, Capital Medical University, Beijing, China2 trials
• Beijing Tongren Hospital, Capital Medical University (East)1 trial
• Capital Medical University (CMU) - Beijing Tongren Hospital1 trial
• Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Glaucoma59 works · 3 trials
• Macular degeneration31 works · 5 trials
• Diabetic eye disease31 works · 3 trials
• Retinitis pigmentosa8 works · 1 trials
• Neuromyelitis optica (NMOSD)5 works · 1 trials